Report #2873729

Received Nov 20, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 62 yrs
State: NC
Recovered: Unknown
Vaccinated: —
Onset: Nov 16, 2025
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEPAB	HEP A + HEP B (TWINRIX)	GLAXOSMITHKLINE BIOLOGICALS	UNK	AZ2A3	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Twinrix late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 62-year-old female patient who received HAB (Twinrix) (batch number 327E3) and (batch number AZ2A3, expiry date 05-FEB-2028) for prophylaxis. Previously administered products included twinrix (received 1st dose on 21-FEB-2025). On 16-NOV-2025, the patient received Twinrix. On 16-NOV-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Twinrix late second dose). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 17-NOV-2025 A pharmacist wanted to know how to proceed with a patient. The Vaccine Administration Facility was the same as Primary Reporter.